EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series
In addition to the prepared remarks, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27th at 4:00 PM ET
6月27日星期四將與enVVeno Medical首席執行官Robert Berman進行現場視頻直播。th美國東部時間下午4:00
IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Thursday, June 27, 2024 at 4:00 PM ET.
加利福尼亞州爾灣/ACCESSWIRE/2024年6月25日/enVVeno Medical Corporation（NASDAQ: NVNO）（"enVVeno"或"本公司"）是一家爲靜脈疾病治療設立新標準的公司。今天宣佈，enVVeno Medical首席執行官Robert Berman將於2024年6月27日下午4點參加虛擬投資者收盤鍾系列活動。
As part of the event, Mr. Berman will discuss the Company's recently reported positive interim venous ulcer healing data showing significant improvement from the Company's SAVVE U.S. pivotal trial for the VenoValve. He will also highlight key safety and efficacy data reported to date from the SAVVE trial and outline the timeline for expected approval the VenoValve.
作爲活動的一部分，Berman先生將會討論公司最近公佈的有關SAVVE美國關鍵試驗對VenoValve的中期治療靜脈潰瘍數據的正面展示，也會突出展示來自SAVVE試驗到目前爲止報告的重要安全和有效數據，並概述VenoValve預期批准的時間表。
In addition to the prepared remarks, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
除了準備好的講話外，還將舉行現場問答環節。Berman先生將在規定時間內儘可能回答儘可能多的問題。
A live video webcast of the presentation will be available on the Events page of the Company's website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
演示的視頻實況將可在本公司網站的事件頁面上得到。兩小時後，再次播放的視頻實況將可被播放，並保持開放90天。
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently performing the final testing necessary to seek approval for the enVVe pivotal trial.
關於enVVeno Medical Corporation
enVVeno Medical（NASDAQ: NVNO）是一家總部位於加利福尼亞爾灣的後期臨床階段醫療器械公司，致力於推進改善靜脈疾病治療標準的創新生物義肢（基於組織）。該公司的主要產品VenoValve是一種首創的手術性替代靜脈瓣膜，用於治療深靜脈慢性靜脈不全（CVI）。公司還正在開發一種非手術性、經導管的替代靜脈瓣膜，用於治療深靜脈CVI，稱爲enVVe。當腿部靜脈內的瓣膜受損時，CVI發生了，導致血液倒流（反流），血液在下肢積聚，靜脈內壓力升高（靜脈高壓），在嚴重情況下形成難以癒合和變成慢性的靜脈潰瘍。無論是VenoValve還是enVVe都是爲了充當單向閥門，以幫助推動血液向上運輸，返回心臟和肺臟。目前VenoValve正在接受SAVVE美國關鍵研究評估，公司目前正在進行最後的測試，以尋求enVVe關鍵試驗的批准。
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(833) 475-8247
投資者聯繫方式：
Jenene Thomas，JTC團隊LLC
NVNO@jtcir.com
(833) 475-8247
SOURCE: enVVeno Medical Corporation
來源：enVVeno Medical Corporation
譯文內容由第三人軟體翻譯。
